pharmaphorumKite keeps pressure on Novartis with CAR-T filingpharmaphorumKite Pharma has completed its filing for its T-cell cancer therapy with the FDA, giving rival Novartis a slender lead in the race to get the first such product to market. Californ… Continue reading
Technology Networks |
Patients’ Immune System May Impact Cancer Immunotherapy
Technology Networks Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute (UPCI). |
Lab News |
Leap forward made in synthetic biology
Lab News Professor Jeff Boeke, from New York University and Sc 2.0 project director, said: “This work sets the stage for completion of designer, synthetic genomes to address unmet needs in medicine and industry. Beyond any one application, the papers confirm … |
YourStory.com |
Mayur Abhaya’s Rs 125-crore stem cell company secures future of likes of Aishwarya Rai’s daughter
YourStory.com His company – Lifecell – has just bought over the stake held by its investor, Helion Ventures, and is looking at maintaining its position as the largest stem cell network in the country. It is launching an on-demand model for sharing cord blood cells. Time To Improve Transplant Access for Seniors with Blood CancersMedPage Today Once considered medical trash, umbilical cord blood is saving the lives of cancer patientsScroll.in |
The Scientist |
More Biomarkers Needed for Cancer Immunotherapy
The Scientist Determining who will benefit from immunotherapy is an enormous challenge. But by taking a comprehensive view—considering protein biomarkers, mutational changes, and immune cell signatures together—I believe we have a promising path forward. Cancer Immunotherapies Treatment Strategies and Product Pipeline Review 2017EIN News (press release) |
|
Making CAR T-Cell Therapy Safer
The Scientist JCAR015 is not the first CAR T-cell therapy to have been associated with patient deaths. In fact, even those trials considered a success sometimes have troubling safety profiles. For example, Novartis’s lead candidate, the CD19-targeting CLT019, … |